Keyphrases
Prospective Cohort Study
100%
Inflammatory Bowel Disease
100%
Crohn's Disease
33%
Ulcerative Colitis
33%
Serious Infection
33%
Inflammatory Bowel Disease Unclassified
33%
Europe
16%
Need to Evaluate
16%
Cancer Risk
16%
Medical History
16%
Quality of Care
16%
Cancer History
16%
Disease-related
16%
Lymphoma
16%
Long-term Benefit
16%
Safety Concerns
16%
Anti-tumor Necrosis Factor (anti-TNF)
16%
Biological Therapy
16%
Prospective Longitudinal Study
16%
Immunomodulator
16%
Methotrexate
16%
Current Therapies
16%
Multicenter Cohort Study
16%
Anti-tumor Necrosis Factor Agents
16%
Long-run Risk
16%
Investigator-initiated
16%
Unique Information
16%
Ustekinumab
16%
Thiopurines
16%
High-grade Dysplasia
16%
Previously Treated
16%
EudraCT
16%
Risk-benefit Ratio
16%
Vedolizumab
16%
6-mercaptopurine (6-MP)
16%
Systemic Steroids
16%
Biologic Monotherapy
16%
Uterine Cervix
16%
Medicine and Dentistry
Prospective Cohort Study
100%
Inflammatory Bowel Disease
100%
Malignant Neoplasm
37%
Infection
25%
Ulcerative Colitis
25%
Mercaptopurine
25%
Cohort Analysis
12%
Tumor Necrosis Factor
12%
Biological Product
12%
Immunomodulating Agent
12%
Crohn's Disease
12%
Medical History
12%
Dysplasia
12%
Patient with Crohn's Disease
12%
Monotherapy
12%
TNF Inhibitor
12%
Uterine Cervix
12%
Methotrexate
12%
Vedolizumab
12%
Risk-Benefit Ratio
12%
Biological Therapy
12%
Azathioprine
12%
Ustekinumab
12%
Pharmacology, Toxicology and Pharmaceutical Science
Prospective Cohort Study
100%
Inflammatory Bowel Disease
100%
Malignant Neoplasm
37%
Infection
25%
Crohn's Disease
25%
Mercaptopurine
25%
Ulcerative Colitis
25%
Cohort Study
12%
Biological Product
12%
Tumor Necrosis Factor
12%
Immunomodulating Agent
12%
Methotrexate
12%
Tumor Necrosis Factor Inhibitor
12%
Medical History
12%
Monotherapy
12%
Azathioprine
12%
Ustekinumab
12%
Dysplasia
12%
Vedolizumab
12%